RFP: Using Real-World Data to Address Prevalence and Treatment of Cardiovascular, Kidney and Metabolic Disease in Cancer Patients and Survivors Grant

The American Heart Association is seeking proposals to study the prevalence and treatment of cardiovascular, kidney, and metabolic diseases among cancer patients and survivors. Given the over 16.7 million cancer survivors in the U.S., this research aims to highlight critical health disparities, identify treatment modalities, and explore shared risk factors. Applications focusing on underrepresented populations and utilizing real-world data sources are especially encouraged, aiming to improve health outcomes in this vulnerable group.

Using Real-World Data to Address Prevalence and Treatment of Cardiovascular, Kidney and Metabolic Disease in Cancer Patients and Survivors
Overview
There are >16.7 million cancer survivors in the United States today. Many of these individuals are at increased risk of morbidity and mortality from noncancer causes, predominantly cardiovascular disease (CVD).1 The risk varies by pre-existing CVD risk factors, cancer type, treatment exposure, and time since cancer diagnosis.2,3,4,5
The purpose of this Request for Proposal (RFP) announcement is to fund research focused on the prevalence and treatment of cardiovascular, kidney and metabolic disease in cancer patients and survivors.
A successful application will address one or more of the following topics:
Defining the prevalence of cardiovascular, kidney, metabolic disease in cancer patients and survivorsIdentifying how these patients are being treated (using real world evidence from hospital systems)Identifying shared cardiometabolic risk factors between cancer and cardiovascular disease Better understand cancers where cardiometabolic risk factors play a role in oncology outcomes, in particular obesity-related cancers (including breast cancer, colorectal cancer, endometrial cancer, ovarian cancer, non-Hodgkin lymphoma and other) Design and implement randomized clinical trials investigating the effects of contemporary cardiometabolic interventions (SGLT2 inhibitors, GLP1 agonists, anti-inflammatory agents) on cardiovascular and cancer outcomesUse real world evidence to test if interventions that reduce cardiometabolic risk improve cardiovascular and cancer outcomes.
We encourage applications that are focused on underrepresented populations. Proposals are encouraged to leverage data sources including de-identified claims data, electronic health records and prospective cohort studies.

Eligibility

You must be a member of this organization to apply for this award - become a member.